Nasdaq: ALT

Altimmune, Inc. (ALT)

Altimmune, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker ALT. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
ALT
Exchange
Nasdaq
SEC CIK
1326190
Official filings
SEC EDGAR

Research ALT

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Altimmune, Inc.'s stock ticker?

Altimmune, Inc. trades under the ticker symbol ALT on Nasdaq. Its SEC Central Index Key (CIK) is 1326190.

Where can I read Altimmune, Inc.'s SEC filings?

The ALT SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Altimmune, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze ALT's financial statements?

The ALT Financials page shows Altimmune, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does ALT compare with its peers and the market?

The ALT Peer Comparison page lines Altimmune, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.